Collaborating on payment models to unlock the potential of multi-indication therapies.

Virtual | 15:00 – 17:00 BST | WEDNESDAY 22 June 2022

16:00 – 18:00 CEST | 10:00 – 12:00 EDT | 09:00 – 11:00 CT


Innovation in drug development is evolving at pace. Individual medicines are increasingly found to benefit patients in a range of indications, within or across diseases, at different stages of disease, as monotherapy or in combination with other therapies as part of treatment regimens. For the growing number of these multi-indication medicines access may be delayed or even denied due to challenges in linking payment with a medicine’s value across indications.

To find the best solutions we must balance many perspectives. First and foremost, patients (and their treating clinicians) want access to the most effective treatments. Payers have accountability for enabling access within the context of the resources and treatment options that are available today. Health care systems more broadly strive to make effective and affordable treatments available and to foster an environment that incentivises the development of those treatments. Those responsible for discovering, developing and bringing innovation to market are motivated by advancing patient care while maintaining a sustainable business model. In order to overcome challenges in the pricing and reimbursement of medicines, we need to take all of these perspectives into consideration.

Our evolving scientific understanding of disease pathology requires health systems to adapt their payment models in ways that recognise clinical benefits in increasingly targeted and multiple population groups. Science is out of step with payment models and it’s time to ask: can we do better?

Join us for our OHE Masterclass where four international experts, along with OHE’s thought leaders, will discuss why change is needed, the challenges arising, and how they can be overcome. In this free two-hour Masterclass delegates will:

  • Be presented with a multi-stakeholder view on the need for and opportunities associated with payment models that recognise value at the indication-level, leveraging the findings of the OHE Consensus Programme and the experience of international experts.
  • Explore insights and learnings: what are the various implementation models, and what can we learn from experience with them to date?
  • Have a forum for questions, answers, and sharing of information amongst participants.


IntroductionGraham Cookson
Panel presentations: recognising indication-level value in payment models for medicines – can patients, payers and industry be aligned in their need and use?Dr Durhane Wong-Rieger
Canadian Organization for Rare Disorders

Prof Luca Pani
University of Miami

Dr Jens Grueger
BCG; University of Washington
Recognising value of multi-indication therapies: can payment by indication benefit payers as well as patients?Dr Amanda Cole
A focus on implementation: payment models and an enabling data environmentDr Ain Aaviksoo
Conclusions of an expert panelDr Amanda Cole
Live panel discussion and open Q&AAll

This is an AstraZeneca organised and funded non-promotional meeting facilitated by OHE.

Veeva ID: Z4-44778
Date of preparation: June 2022